Navigation Links
Oncothyreon regains compliance with NASDAQ listing requirements
Date:3/16/2009

esults to differ materially from those projected in forward-looking statements, including the risks associated with the availability and adequacy of financing, our financial condition and results of operations, general economic factors, achievement of the results we anticipate from our clinical trials with our products and our ability to adequately obtain and protect our intellectual property rights. Although we believe that the forward-looking statements contained herein are reasonable, we can give no assurance that our expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of our risks and uncertainties, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on EDGAR and in Canada on SEDAR. Oncothyreon does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncothyreon to present at Invest Northwest 2009
2. Oncothyreon reports full year and fourth quarter 2008 financial results
3. Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
4. Oncothyreon to present at BIO CEO & Investor Conference 2009
5. Oncothyreon reports third quarter 2008 financial results
6. Oncothyreon to present at Rodman & Renshaw Annual Global Investment Conference
7. Oncothyreon announces November 6th webcast of third quarter 2008 financial results and corporate update conference call
8. Oncothyreon to present at BIO Investor Forum 2008
9. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
10. Oncothyreon announces prioritization plan for development programs
11. Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Achieved primarily through a proprietary paraffin and stain additive, ... better detail than the industry standard. But because ... methods, it needed another medium to measure its detail. ... reference because it represents the highest standard of detail ... discovery days of Ultralight Histology was to reverse engineer ...
(Date:5/4/2015)... --  Intrexon Corporation (NYSE: XON ) today ... after the market closes on May 11, 2015.  The ... 5:30 PM ET to discuss the results and provide ... may be accessed by dialing 1-888-346-3959 (Domestic US) and ... Call."  Participants may also access the live webcast through ...
(Date:5/1/2015)... , May 1, 2015 /PRNewswire/ - BioAmber Inc. ... sustainable chemicals, today announced that it has priced an underwritten ... at a price of $9.00 per share, and granted ... purchase up to an additional 585,000 shares of its ... be $35.1 million.  The offering is expected to close on ...
(Date:5/1/2015)... , May 1, 2015 Albany Molecular Research ... William S. Marth , AMRI,s President and Chief Executive ... Lynch 2015 Health Care Conference on Wednesday, May 13, ... audio webcast of the presentation can be accessed at ... The webcast will be archived for 90 ...
Breaking Biology Technology:Intrexon to Announce First Quarter 2015 Financial Results on Monday, May 11, 2015 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3AMRI to Present at the Bank of America Merrill Lynch 2015 Health Care Conference 2
... Chakrabarty is modest about the role he played ... willing to do the boasting for him. , , ... patent life forms, visited Wisconsin this week to lecture ... biotechnology program. Asked if he understood the full impact ...
... transportation, and perhaps even the 2016 Olympic games are potential ... according to Milwaukee Mayor Tom Barrett . , ... in a forum held by the Wisconsin Innovation Network, said ... and their plans to develop the "IQ Corridor" along Interstate ...
... and CEO of ZyStor Therapeutics, Inc. is ... of this year's Midwestern bioscience forum. , ,As a ... companies with another presenter, Dr. Irene Hrusovsky, CEO of ... diagnostic products. , ,Like many of the attendees, Peterson ...
Cached Biology Technology:Father of life patents downplays historic role 2Father of life patents downplays historic role 3Cieslewicz, Barrett talk economic collaboration 2Cieslewicz, Barrett talk economic collaboration 3Cieslewicz, Barrett talk economic collaboration 4ZyStor to exhibit cell disorder treatments 2
(Date:4/2/2015)... Germany , April 2, 2015 ... fingerprint tests DERMALOG by far outperforms the strongest ... always maintaining high accuracy, the system is capable ... Hence, the speed proves up to be ten ... faster than its runner-up performance.      ...
(Date:4/2/2015)... 2, 2015 Fingerprint Cards (FPC) ... FPC1025 from the distributor World Peace Industrial Group (WPI), ... 2015 although the major part of the shipments will ... used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK ...
(Date:3/31/2015)...  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant ... Defined Network Architecture (ET Software DNA® 2.0) platforms and ... $20.4 million for the year ended December 31, 2014 ... year ended December 31, 2013. At ... its multi-year transition away from its legacy landline business ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... data to a Phase 2 trial conducted by the ... an 89% survival rate in mantle cell lymphoma patients. ... Historically, patients with this type of lymphoma only have ... 20% chance of surviving 5 years. BiovaxID, an investigational ...
... Florida scientists have found that people have an ancient ... by a jawless, eel-like fish. , It turns out ... road than almost all other backboned animals, may not ... the genetics that govern their skeletal development, according to ...
... in humans are genetically based. The influence of ... of humans are complicated by a multitude of cultural ... Alcoholism: Clinical & Experimental Research use rhesus ... consumption. Results indicate that, just as with humans, ...
Cached Biology News:BiovaxID?yields 89 percent survival in patients with aggressive non-Hodgkins 2UF scientists reveal ancient origin of vertebrate skeleton 2UF scientists reveal ancient origin of vertebrate skeleton 3Genetic and environmental influences on alcohol consumption among rhesus monkeys 2
Mouse monoclonal antibody raised against a partial recombinant ZNF167. NCBI Entrez Gene ID = ZNF167...
... monoclonal [HDAC8-48] to HDAC8 Regulation ... several mechanisms such as DNA methylation, ... modifications of histones, which include the ... groups of lysine residues present in ...
... polyclonal antibody raised against a ... Immunogen: SLC22A3 (NP_068812, ... partial recombinant protein with GST ... Number: NM_021977 ...
...
Biology Products: